Molecular Pathways and Potential Therapeutic Targets of Refractory Asthma
Biology,
Journal Year:
2024,
Volume and Issue:
13(8), P. 583 - 583
Published: Aug. 1, 2024
Asthma
is
a
chronic
inflammatory
lung
disease.
Refractory
asthma
poses
significant
challenge
in
management
due
to
its
resistance
standard
therapies.
Key
molecular
pathways
of
refractory
include
T2
inflammation
mediated
by
Th2
and
ILC2
cells,
eosinophils,
cytokines
including
IL-4,
IL-5,
IL-13.
Additionally,
non-T2
mechanisms
involving
neutrophils,
macrophages,
IL-1,
IL-6,
IL-17
mediate
corticosteroid
resistant
phenotype.
Mediators
alarmins
(IL-25,
IL-33,
TSLP)
OX40L
have
overlap
between
may
signify
unique
inflammation.
Therapies
that
target
these
mediators
proven
be
effective
reducing
exacerbations
improving
function
subsets
severe
patients.
However,
there
are
patients
with
who
do
not
respond
approved
Small
molecule
inhibitors,
such
as
JAK-inhibitors,
monoclonal
antibodies
targeting
mast
TNFα,
under
investigation
for
their
potential
modulate
involved
asthma.
Understanding
heterogeneity
identifying
essential
developing
therapeutic
interventions
unresponsive
currently
biologics.
Further
needed
develop
personalized
treatments
based
on
insights
potentially
offer
more
this
complex
Language: Английский
Direct comparative study of anti-IgE and anti-IL4Rα therapy effectiveness in patients with severe allergic and mixed bronchial asthma
Meditsinskiy sovet = Medical Council,
Journal Year:
2024,
Volume and Issue:
9, P. 74 - 86
Published: June 6, 2024
Introduction
.
There
is
insufficiency
of
direct
comparative
studies
genetically
engineered
biological
drugs
(GEBD)
for
severe
bronchial
asthma
(SA)
treatment
in
scientific
databases.
Aim
To
compare
omalizumab
and
dupilumab
effectiveness
patients
with
allergic
mixed
SA
real
clinical
practice.
Materials
methods
The
study
included
an
component
from
regional
registry
Sverdlovsk
region.
data
(n
=
68)
27)
treated
62)
33)
were
analyzed.
Therapy
was
determined
12
months
general
group
No.
1,
2
3
according
to
the
following
indicators:
control
level
(ACT),
proportion
uncontrolled
asthma,
need
systemic
glucocorticosteroids
(SGCS)
short‐acting
beta
agonists
(SABA),
basic
therapy
volume,
exacerbations
number,
emergency
calls
hospitalizations,
forced
expiratory
volume
first
second
(FEV
),
assessment
life
quality
(AQLQ
SNOT-22).
Control
evaluation
visits
conducted
before
start,
after
4
biologics
taking.
Results
In
general,
during
targeted
receiving
statistically
significant
positive
dynamics
observed
13
evaluated
indicators;
–
9
indicators.
When
analyzing
such
indicators
as,
ACT,
taking
SGCS,
SA,
FEV
,
revealed
all
3.
Conclusions
Patients
respond
equally
well
dupilumab.
At
same
time,
a
tendency
towards
advantage
phenotype
disease
revealed.
Language: Английский